Quest Diagnostics IncorporatedDGX Quest Diagnostics Incorporated fair value $185–$268

Quest Diagnostics is a mature, highly cash-generative leader in the US diagnostic testing market. Its robust national network provides durable scale advantages, supporting consistent free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics. generation and a reliable, growing dividend. With an implied ~19.4x forward P/EForward P/ECurrent share price divided by the next-twelve-months EPS estimate. Less backward-looking than trailing P/E and a better cross-sectional comparison when earnings are growing or normalizing., DGX is positioned as a defensive healthcare compounding asset.

• Scale Advantage
  Unmatched national laboratory network lowers per-test processing costs.
• Switching Costs
  Deep integration with hospital IT systems and payer networks.
• Bull thesis
  Valuation: Shares are undervalued, supported by a $226.02 composite midpoint tightly aligned with the $223.25 internal valuation cross-checks.